Navigation Links
New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
Date:5/20/2008

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM)(1). Patients participating in the study were ages 18 years and older with moderate to severe asthma(1) and had been previously treated with inhaled corticosteroids(1). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.

Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p<0.001), dosing management (p<0.001), and timely relief of symptoms (p=0.037)(1). Patients receiving budesonide/formoterol combination therapy fixed dose reported significantly greater satisfaction for timely relief of symptoms (p=0.002) and feeling the medication begin to work (p=0.02) compared to patients receiving fluticasone/salmeterol combination therapy(1). Budesonide/formoterol combination therapy is not indicated for adjustable dosing in the U.S.

"These data showed that patients treated with budesonide/formoterol combination therapy fixed dose were more satisfied with the timeliness of their symptom relief than those patients treated with fluticasone/salmeterol combination therapy," said lead investigator Richard O'Connor, MD, of the University of California-San Diego.

About the ATSM

Patient satisfaction was assessed using the recently validated 11-item Asthma Treatment Satisfaction Measure (ATSM)(1). Scores range from 0-100, with the higher scores equaling greater satisfaction(1). Categories included symptom relief, onset of action, sensations that medication
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
2. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
3. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
4. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
5. Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
7. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
8. CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
11. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK, Iceland, November 24 ...nced the approval of all of its,"first day" motion... Delaware,(the "Bankruptcy Court"). deCODE last we...pter 11 of the United States Bankruptcy Code with ... by the Bankruptcy Court allow the company to cont...
(Date:11/24/2009)...24 /PRNewswire-Asia/ -- Shanghai Biolaxy announced...(SFDA) has approved the,investigational new drug a...lin), an innovative insulin formulation to treat d...ate its first phase I clinical study. , D... glucose and poor,metabolism. The complications of...
(Date:11/24/2009)...ndpoint has been met for patients with advanced-st...EBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEtern...ompany"), a global biopharmaceutical company focus...ced positive efficacy data from a Phase 2 study wi...108 (formerly AN-152), in patients with advanced o...
(Date:11/24/2009)...2009 Arena Pharmaceutica...he company is scheduled to present at the Piper Ja...er 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. P...ork City. Jack Lief, Arena,s President and Chief E...iew of the company, including its clinical develop...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...cts of Cost Savings Initiatives Quantified - ...dance -, HOPKINTON, Mass., April 24 Caliper Life...er of tools and services for,drug discovery and li...ented a plan to consolidate its west coast busines...improve productivity and effectiveness of,its rese...
...RY, N.J., April 24 Amicus Therapeutics,Inc. (Nasd... President and,Chief Executive Officer, will prese... Healthcare Unplugged Conference on Wednesday, Apr...in Key Biscayne, Florida., The presentation will ...icus, website at http://www.amicustherapeutics.co...
..., Pa., April 24 Cephalon, Inc.,(Nasdaq: CEPH ) t...fication,Notice Letter relating to an Abbreviated ...Food and Drug Administration (FDA) by Watson,Labor...ell a generic,version of FENTORA(R) (fentanyl bucc...leges that the U.S. Patent Numbers 6,200,604 and 6...
Other Biology Technology:Caliper Life Sciences Reports West Coast Consolidation of Operations 2Caliper Life Sciences Reports West Coast Consolidation of Operations 3Caliper Life Sciences Reports West Coast Consolidation of Operations 4Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 2Cephalon Notified of Generic Fentanyl Buccal Tablet Filing 3
(Date:11/26/2009)...re some of the Ocean,s most distinctive residents....strange head shape, says Michelle McComb from Flo...he shark,s vision. ,Perhaps their visual field has...Comb, giving the sharks excellent stereovision and...here were two schools of thought on this theory. I...
(Date:11/26/2009)...t in eight European countries has shown that closi...andemic could have a significant role in reducing ...pen access journal BMC Infectious Diseases compa... weekends/holidays, finding that they were reduced...t and Antwerp University, Belgium, led a team of E...
(Date:11/26/2009)...esistant Staphylococcus Aureus ) and other drug-r...emperature plasma prototype devices have been deve...tericidal cocktails. , Two prototype devices hav...f healthy skin (e.g. hands and feet) in hospitals ... threat; and another to shoot bacteria-killing age...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2School closure could reduce swine flu transmission by 21 percent 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 1DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 12597 3FDA Accepts Final Section of NDA Filing for LUCASSIN 28R 29 48733 1FDA Accepts Final Section of NDA Filing for LUCASSIN 28R 29 48733 2Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 1Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 2Volvo Invites Customers to Cut Their Service Bills While Supporting Pediatric Cancer Research 48729 3
...ltimore, MD) In the first neuroimaging study to e...searchers at the Kennedy Krieger Institute have un...l basis of autism. The study, published online in ...ss, compared the brain activity of children with h...ing peers while performing a simple motor tasktapp...
... biotechnologies that allow scientists to quickly ...le DNA analysis are being creatively deployed for ...isease. , The University of Ghana, supported by t... is pioneering the use of DNA "barcodes" to map me... lymphatic filariasis (LF), commonly known as elep...
...e human brain stores some kinds of memories for a ...t things, our gray matter also creates temporary m...the few seconds these visual memories exist. For d...memories don,t suddenly disappear, but grow gradua...nds. , Now researchers at the University of Calif...
Other Biology News:First neuroimaging study examining motor execution in children with autism reveals new insights 2First neuroimaging study examining motor execution in children with autism reveals new insights 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4Some short-term memories die suddenly, no fading 2
Goat Anti-T7 tag Polyclonal Antibody, Agarose Conjugated from GeneTex
Goat Anti-T7 Polyclonal Antibody, Agarose Conjugated from GeneTex
Rabbit Anti-Olfactory Receptor LS189744 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-C/EBPdelta Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: